Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.68 |
| ▸ | SLC6A9 | P48067 | 13/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.52 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.51 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378266 | 1.00 | GPR119 (0.68) | GPR119SLC6A9KCNH2SLC6A5EGLN2 | |
| SCHEMBL8280131 | 0.90 | GPR119 (0.59) | GPR119SLC6A9SLC6A5EGLN2 | |
| SCHEMBL3486449 | 0.90 | GPR119 (0.61) | GPR119 | |
| SCHEMBL24216600 | 0.88 | GPR119 (0.54) | GPR119SLC6A9 | |
| SCHEMBL532948 | 0.86 | GPR119 (0.55) | GPR119EGLN2 | |
| SCHEMBL709010 | 0.86 | GPR119 (0.55) | GPR119EGLN2 | |
| SCHEMBL25369348 | 0.86 | GPR119 (0.55) | GPR119SLC6A9KCNH2EGLN2 | |
| SCHEMBL13156287 | 0.85 | GPR119 (0.54) | GPR119EGLN2 | |
| SCHEMBL30062534 | 0.85 | GPR119 (0.54) | GPR119EGLN2 | |
| SCHEMBL356713 | 0.85 | GPR119 (0.54) | GPR119KCNH2EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118055933-A | Selective PARP1 inhibitors and uses thereof | 成都百裕制药股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| CN-116640122-A | IKZF 2 Degradation agent, pharmaceutical composition containing degradation agent and application of degradation agent | 苏州国匡医药科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023155710-A1 | IKZF2 DEGRADATION AGENT, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 苏州国匡医药科技有限公司 | 2023-08-24 | — | — | WO | disclosed |
| US-20230190760-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190760-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| EP-4192450-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| CN-116194438-A | Advantageous treatment of Ikaros or Aiolos mediated disorders | C4医药公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023088408-A1 | SELECTIVE PARP1 INHIBITOR AND APPLICATION THEREOF | 成都百裕制药股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | GPR119 58/4885SLC6A9 4629/4885KCNH2 2282/4885 |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | GPR119 39/4885SLC6A9 4791/4885KCNH2 1633/4885 |
| US-20230190760-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | IKZF1, IKZF3, CRBN | GPR119 4209/4885SLC6A9 4842/4885KCNH2 4234/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | GPR119 223/4885SLC6A9 1226/4885KCNH2 211/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | GPR119 4392/4885SLC6A9 4873/4885KCNH2 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.